<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170211032503N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-20</date_registration>
      <primary_sponsor>Vision health research center</primary_sponsor>
      <public_title>Using exosome  to treat severe dry eyes</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the therapeutic effect of eye drops obtained from Wharton's jelly stem cell exosomes in patients with severe dry eyes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-04-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75189</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Severe dry eye.</hc_freetext>
      <i_freetext>Intervention Group: A group of 30 individuals diagnosed with dry eye disease  which will referred to the Vision Health Clinic will enrolled in the study. The medication consists of eye drops containing stem cell-derived exosomes, which the patient will instill into their eyes four times a day for 12 weeks..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All the results obtained based on the disease improvement process along with the age and sex of the patient will be available.

When:
All the results obtained based on the disease improvement process along with the age and sex of the patient will be available after the completion of the three-month follow-up period.

To whom:
It will be available for researchers working in academic and scientific institutions

Conditions:
In the case of obtaining permission from experts, the relevant applicants can access the data at the designated time. Only encrypted data and no personal patient profiles will be accessible.

Where to obtain:
The email address along with the contact number of the respondents will be provided to the applicants

How to obtain:
After the completion of the three-month treatment period, after receiving an email from the applicant, the documents will be provided to the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Aghamollaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 17, 5th floor, No. 8, Second Alley, Vali Asr Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1516747418</zip>
        <telephone>+98 21 8819 6862</telephone>
        <email>aghamolaei22@gmail.com</email>
        <affiliation>Vision health research center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Khosrow Jadidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 17, 5th floor, No. 8, Second Alley, Vali Asr Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1516747418</zip>
        <telephone>+98 21 8819 6862</telephone>
        <email>kh.jadidi@gmail.com</email>
        <affiliation>Vision health research center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People with severe dry eye based on symptoms in at least one eye: dryness, burning sensation, foreign body sensation, discomfort in the ocular surface or visual fatigue
Failure to respond to routine treatments
Tear secretion test (Schirmer test) both eyes ≤ 10 mm / 5 minutes.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Those who are allergic to any of the drug components in this study.
Pregnant or lactating women
Patients with active fungal, bacterial or viral keratitis or conjunctivitis
Suffering from serious heart, lung, liver, or kidney diseases;
Patients with Diabetes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H04.129</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Dry eye syndrome of unspecified lacrimal gland</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: A group of 30 individuals diagnosed with dry eye disease  which will referred to the Vision Health Clinic will enrolled in the study. The medication consists of eye drops containing stem cell-derived exosomes, which the patient will instill into their eyes four times a day for 12 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The percentage of patients with increasing of Tear Film Break-up Time. Timepoint: Before intervention, one week, 4 weeks and 12 weeks after intervention. Method of measurement: The time required for dry spots to appear on the surface of the eye after blinking is in seconds. A positive change from baseline indicates improvement in each eye.</prim_outcome>
      <prim_outcome>Ocular Surface Staining. Timepoint: Before intervention, one week, 4 weeks and 12 weeks after intervention. Method of measurement: An area of the cornea that is stained with fluorescein dye and it will be assessed using a slate lamp microscope. Ocular surface damage will be measured by slit lamp examination after staining with non-toxic sodium fluorescein. Corneal and conjunctival staining will be graded based on the National Eye Institute (NEI) imaging scale. The lower the score has the less dry eye symptoms the patient. A negative change from baseline indicates improvement in each eye.</prim_outcome>
      <prim_outcome>The volume of tear. Timepoint: Before intervention, one week, 4 weeks and 12 weeks after intervention. Method of measurement: A paper strip is placed on the eye under the lower eyelid for a certain period of time. The length of the tear-soaked strip will be measured in millimeters. A positive change from baseline indicates improvement in each eye.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Uncorrected visual acuity. Timepoint: Before intervention,  1week, 1 month and 3 months after intervention. Method of measurement: Measurement of vision based on Snellen chart.</sec_outcome>
      <sec_outcome>Best corrected visual acuity. Timepoint: Before intervention,  1week, 1 month and 3 months after intervention. Method of measurement: Measurement of vision based on Snellen chart.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>This study will not have any other financial source</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-01</approval_date>
        <contact_name>Ethics Committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>Headquarters of Smenan University of Medical Sciences, Basij Blvd. Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
